What is GlycoSeLect?
GlycoSelect Ltd. operates at the intersection of biotechnology and analytical chemistry, specializing in the engineering of Recombinant Prokaryotic Lectins (RPLs). These advanced bioaffinity proteins represent a paradigm shift in the detection, analysis, and isolation of glycosylated biomolecules. By providing a scalable alternative to traditional purification methods, GlycoSelect addresses critical bottlenecks in biopharmaceutical research and development. The company's core value proposition lies in its ability to deliver high-precision tools that enhance the efficiency of complex biological workflows, thereby supporting the broader life science industry in its pursuit of next-generation therapeutic discovery.
How much funding has GlycoSeLect raised?
GlycoSeLect has raised a total of $528K across 1 funding round:
Angel/Seed
$528K
Angel/Seed (2017): $528K, investors not publicly disclosed
Key Investors in GlycoSeLect
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for GlycoSeLect?
With this major strategic investment, GlycoSelect is poised to scale its production capabilities to meet the growing demand for high-affinity glycoselective tools. The company's forward-looking strategy focuses on deepening its penetration into the biopharmaceutical market, where the demand for reliable, scalable purification technologies remains high. Future growth will likely center on expanding the application range of its RPL platform, potentially moving into clinical-grade manufacturing support. As the firm matures, the focus will shift toward establishing long-term partnerships with global pharmaceutical entities, ensuring that its proprietary protein technology becomes a standard component in the development of complex biologics and diagnostic assays.
See full GlycoSeLect company page
